H.C. Wainwright analyst Emily Bodnar initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Buy rating and a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage